^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

EGFR negative

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
14h
Patient Age and EGFR-positive Non-small Cell Lung Cancer: A Multicenter Retrospective Study. (PubMed, Anticancer Res)
Patients in their 70s and 80s with non-small cell lung cancer were relatively frequently EGFR gene-positive. To avoid missing out on treatment opportunities, EGFR gene testing should also be performed on patients in this age group.
Retrospective data • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR L858R • EGFR exon 19 deletion • EGFR positive • EGFR negative
7d
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. (PubMed, J Clin Oncol)
The addition of palbociclib to fulvestrant did not improve PFS versus fulvestrant alone among patients with hormone receptor-positive/HER2- MBC whose disease had progressed on a previous CDK4/6i plus AI. The increased PFS seen with the addition of avelumab warrants further investigation in this patient population.
P2 data • Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
|
HER-2 positive • HR positive • HER-2 negative • EGFR positive • EGFR negative
|
Ibrance (palbociclib) • Bavencio (avelumab) • fulvestrant
24d
Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial (clinicaltrials.gov)
P3, N=304, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Initiation date: Feb 2024 --> Nov 2024
Enrollment open • Trial initiation date • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
ALK translocation • EGFR negative
|
Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
28d
Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=37, Recruiting, Chinese University of Hong Kong | Not yet recruiting --> Recruiting | Initiation date: Nov 2024 --> Feb 2024
Enrollment open • Trial initiation date
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR negative
|
Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
29d
EGFR and HER2 expression in cervical cancer patients in Ibadan, Nigeria. (PubMed, Ecancermedicalscience)
HER2 was overexpressed in two cervical tissue samples in this study and may be of poor interest as a potential target in the management of cervical cancer patients. Large prospective multi-institutional studies should be considered to further explore the relationship between EGFR and survival in cervical cancer patients.
Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 expression • EGFR expression • EGFR positive • EGFR negative
1m
Expression of EGFR and p16 in Squamous Cell Carcinoma of External Auditory Canal. (PubMed, Kobe J Med Sci)
In the patients with T3 & T4a EACSCC, prognosis of the patients with positive p16 expression EACSCC tended to be better than those with negative p16 expression. These results suggest the clinical significance of EGFR and p16 expressions in the patients with advanced EACSCC to predict oncological outcomes.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR expression • EGFR negative • CDKN2A negative
1m
Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=37, Not yet recruiting, Chinese University of Hong Kong | Initiation date: Nov 2023 --> Nov 2024
Trial initiation date
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR negative
|
Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
2ms
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101). (PubMed, Cancer Sci)
In patients with unresectable stage III NSCLC with EGFR mutation, durvalumab after CRT is potentially safe and effective. This may be a suitable treatment sequence for these patients.
Clinical • Journal • Real-world evidence • PD(L)-1 Biomarker • Real-world
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR positive • EGFR negative
|
Imfinzi (durvalumab)
3ms
Lower Plasma Amyloid Beta - 42 Levels Associated With Worse Survival in Patients With Glioma. (PubMed, In Vivo)
This study investigated serum Aβ42 levels as a potential biomarker for glioma. The results showed that low serum Aβ42 levels were associated with EGFR expression and poor PFS and OS. Overall, these findings suggest a potential role of Aβ42 as a prognostic marker in astrocytomas.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR expression • EGFR negative
3ms
Osimertinib covalently binds to CD34 and eliminates myeloid leukemia stem/progenitor cells. (PubMed, Cancer Res)
Clinical responses were observed in two CD34high AML patients who were treated with osimertinib on a compassionate-use basis. These findings reveal the therapeutic potential of osimertinib for treating CD34high AML and CML and describe an EGFR-independent mechanism of osimertinib-induced cell death in myeloid leukemia.
Journal
|
CD34 (CD34 molecule)
|
EGFR negative
|
Tagrisso (osimertinib)
4ms
Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR) (clinicaltrials.gov)
P1/2, N=34, Active, not recruiting, Sangamo Therapeutics | Recruiting --> Active, not recruiting | Trial completion date: Feb 2024 --> Sep 2025 | Trial primary completion date: Dec 2023 --> Apr 2025
Enrollment closed • Trial completion date • Trial primary completion date • Gene therapy
|
EGFR negative
4ms
Consolidation therapy of Adebrelimab for stage III unresectable NSCLC after concurrent radiotherapy and chemotherapy (cCRT combined with or without Adebrelimab) (ChiCTR2300075011)
P4, N=120, Recruiting, Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital
New P4 trial
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
MET amplification • ALK fusion • ALK mutation • MET mutation • ROS1 mutation • EGFR negative
|
cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • adebrelimab (SHR-1316)
4ms
New P2 trial
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR negative
|
adebrelimab (SHR-1316)
4ms
Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation. (PubMed, Exp Hematol Oncol)
These findings indicated that a ''YB-1/PARP1'' loop conferred resistance to CDK4/6 inhibitors. Furthermore, interrupting the loop can enhance tumor killing in the xenograft tumor model, which provides a promising strategy against drug resistance in breast cancer.
Journal • PARP Biomarker
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HER-2 expression • EGFR negative • PARP1 elevation
5ms
Intratumoral thrombosis as a histological biomarker for predicting epidermal growth factor receptor alteration and poor prognosis in patients with glioblastomas. (PubMed, J Neurooncol)
Aberrant but exquisitely regulated EGFR can induce thrombosis in non-MVP vessels in the tumor invasion area and then promote palisading necrosis, followed by hypoxia, abnormal angiogenesis, and further tumor cell invasion.
Journal
|
EGFR (Epidermal growth factor receptor) • CD34 (CD34 molecule) • MVP (Major Vault Protein)
|
EGFR amplification • EGFR expression • EGFR wild-type • EGFR negative • CD34 positive
5ms
Clinicopathologic Factors affecting response in patients with Estrogen receptor-positive and Human Epidermal Growth Factor Receptor-negative breast cancer receiving neoadjuvant chemotherapy (SABCS 2023)
Our analysis revealed that patients with higher levels of Ki-67 and lower level of PR expression were more likely to achieve pCR or PR. Also, decrease in Ki-67 index was confirmed to be an important prognostic factor of ER+ HER2- breast cancer. A combination of clinical and molecular factors, such as tumor size, progesterone receptor expression, and Ki-67 expression, can be used to optimize treatment plans and improve outcomes for the patient population.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • AR (Androgen receptor)
|
HER-2 positive • ER positive • HR positive • HER-2 negative • HER-2 expression • EGFR negative • AR expression • HR positive + HER-2 negative • PGR expression • PTEN mutation + HR positive
5ms
Exploring the correlation between HER2 alterations and F-FDG PET/CT metabolic parameters and their prognostic value in EGFR-negative non-small-cell lung cancer patients. (PubMed, J Cancer Res Clin Oncol)
The study revealed that low pSUVmax was associated with HER2 alterations in EGFR-negative NSCLC patients, moreover HER2 mutation and HER2 amplification exhibited distinct F-FDG metabolic and clinical characteristics. Furthermore, it explored the prognostic value of HER2 alterations and F-FDG PET/CT metabolic parameters of pSUVmax in EGFR-negative NSCLC patients.
Journal • FDG PET
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative • EGFR negative
5ms
AI-based intra-tumor heterogeneity score of Ki67 expression as a prognostic marker for early-stage ER+/HER2- breast cancer. (PubMed, J Pathol Clin Res)
Ki67CL score is shown to be highly significant compared with the standard Ki67 index. In addition, we show that the proposed Ki67CL score can help identify luminal BC patients who can potentially benefit from adjuvant chemotherapy.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • EGFR negative
5ms
New P3 trial • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
ALK translocation • EGFR negative
|
Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
5ms
Clinical role of CYP1B1 gene polymorphism in prediction of postoperative chemotherapy efficacy in NSCLC based on individualized health model. (PubMed, Open Life Sci)
In the EGFR-negative group, 13 of the 36 patients relapsed. It can be considered that CYP1B1 gene polymorphism has a good curative effect in postoperative chemotherapy of NSCLC, and it can effectively control the recurrence rate of cancer.
Journal
|
EGFR (Epidermal growth factor receptor) • CYP1B1 (Cytochrome P450 Family 1 Subfamily B Member 1)
|
EGFR negative
5ms
Enrollment closed
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative
|
Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
6ms
Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong (ESMO Asia 2023)
The liquid-first approach enhances the yield of rare mutations by tissue NGS which is resource-dependent. It benefits regions where tissue biopsy is a rate limiting factor and EGFR mutations are prevalent.
Clinical • Next-generation sequencing • Metastases
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
TP53 mutation • BRAF mutation • PIK3CA mutation • EGFR T790M • EGFR exon 20 insertion • MET exon 14 mutation • MET mutation • EGFR exon 20 mutation • EGFR negative • EGFR mutation + PIK3CA mutation • EGFR exon 20 insertion + EGFR T790M • HER-2 exon 23 mutation
|
cobas® EGFR Mutation Test v2 • Oncomine Precision Assay
6ms
Difference in Radiosensitivity Depending on the Presence and Absence of EGFR Mutations: Clinical and In Vitro Analyses. (PubMed, Int J Radiat Oncol Biol Phys)
Our data suggest that patients with EGFR mutation-positive NSCLC are more radiosensitive than those with negative EGFR mutations.
Preclinical • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR negative • EGFR H1975
6ms
Atezolizumab for EGFR-mutated Non-small Cell Lung Cancer Patients: An Observation Study in Ibaraki Group (ATTENTION-IBARAKI). (PubMed, Anticancer Res)
Efficacy of atezolizumab in EGFR-mutated NSCLC patients could be comparable to that for EGFR-negative patients. To prolong the survival of EGFR-mutated NSCLC patients, appropriate selection and sequencing of EGFR for tyrosine kinase inhibitors, as well as immune checkpoint inhibitors, anti-tumor agents, and anti-angiogenic agents are important.
Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR negative
|
Tecentriq (atezolizumab)
6ms
Trial suspension
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative
|
Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
6ms
New P2 trial
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR negative
|
Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
7ms
A study of clinical and molecular characteristics in bilateral primary breast cancer. (PubMed, Cancer Med)
Our study suggested that BPBC may tend to be lobular carcinoma and have the HR+/HER2- subtype. Although our study did not find specific germline and somatic mutations in BPBC, more research is needed for verification.
Journal • BRCA Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • BRCA2 (Breast cancer 2, early onset)
|
TP53 mutation • HR positive • HER-2 negative • EGFR negative
7ms
Difference in Radiosensitivity Depending on the Presence and Absence of EGFR Mutations: Clinical and In Vitro analyses (ASTRO 2023)
Our data suggest that patients with EGFR mutation-positive NSCLC are more radiosensitive than those with negative EGFR mutations.
Preclinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR negative • EGFR H1975
7ms
Journal • Metastases
|
TTF1 (Transcription Termination Factor 1) • NKX2-1 (NK2 Homeobox 1)
|
EGFR mutation • EGFR negative • NKX2-1 expression
7ms
Precise subtyping reveals immune heterogeneity for hormone receptor-positive breast cancer. (PubMed, Comput Biol Med)
In addition, these conserved subgroups were broadly validated on external validation datasets. CMBR identified the molecular signature of HR+ breast cancer subgroups, providing valuable insights into personalized treatment strategies and management options.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • EGFR positive • EGFR negative
8ms
LUNG ADENOCARCINOMA MIMICKING INTERSTITIAL LUNG DISEASE: A CASE SERIES (CHEST 2023)
Mucinous lung adenocarcinoma can closely mimic autoimmune ILD, and this variant of lung cancer may be associated with a worse prognosis. Clinicians should consider early tissue sampling to avoid delays in diagnosis.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • NKX2-1 (NK2 Homeobox 1)
|
PD-L1 expression • ALK mutation • EGFR negative
8ms
Trial completion
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR negative
|
cisplatin • carboplatin • Focus V (anlotinib) • pemetrexed
8ms
ctDNA Positivity Is a Clinical Prognosis Biomarker in Patients with EGFR ex20ins+ NSCLC (IASLC-WCLC 2023)
Introduction: Mobocertinib is an oral tyrosine kinase inhibitor that received accelerated approval as a single agent to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations who received prior platinum-based chemotherapy... Patients who were negative for EGFR ex20ins ctDNA at baseline had a better outcome than patients who had detectable EGFR ex20ins ctDNA at baseline. Similarly, patients with ctDNA-negative status for EGFR ex20ins at C3D1 achieved a better outcome than patients with positive or increased EGFR ex20ins VAF at C3D1. These results warrant further testing of ctDNA as a prognostic biomarker in patients with EGFR ex20ins+ NSCLC.
Clinical • Circulating tumor DNA • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR negative
|
FoundationOne® Liquid CDx • TruSight Oncology 500 Assay
|
Exkivity (mobocertinib)
8ms
Real-World Outcomes with Immunotherapy Compared to Chemoimmunotherapy in Metastatic NSCLC with High PDL1 Expression (IASLC-WCLC 2023)
Although there was a marginal difference in TTNT between the two treatment groups in the unadjusted analysis, this did not translate to a statistically significant difference in survival among patients who received ICI+Chemo compared to ICI alone. This finding may have an impact on treatment patterns, given the impact of chemotherapy on patient quality of life. Future research will re-examine existing endpoints with greater follow-up time, as the insufficient follow-up time may have had an impact on results.
Clinical • Real-world evidence • PD(L)-1 Biomarker • IO biomarker • Real-world • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
PD-L1 expression • PD-L1 overexpression • EGFR expression • EGFR negative
8ms
Benefits of Afatinib and Osimertinib in a Patient with Lung Adenocarcinoma Harboring EGFR19Del/T790M/G724S Mutation (IASLC-WCLC 2023)
She was treated with intrathoracic infusion chemotherapy (pemetrexed 200mg+nedaplatin 20mg) on October 11, 2018...Based on the above findings, the patient was administered with gefitinib 250 mg daily as first-line therapy on November 15, 2018, and achieved partial response (PR)...On January 25, 2022, the patient was hospitalized for shortness of breath, and received intrathoracic Infusion chemotherapy (cisplatin 80mg)... The combination therapy of afatinib and osimertinib could be a new therapeutic option for patients with lung adenocarcinoma harboring EGFRG724S/T790M/19Del mutation.
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 19 deletion • EGFR T790M • EGFR negative • EGFR G724S • EGFR T790M negative
|
cisplatin • Tagrisso (osimertinib) • Gilotrif (afatinib) • gefitinib • pemetrexed • Aqupla (nedaplatin)
8ms
The Prognostic Impact of Postoperative EGFR Mutation Status in Lung Cancer Patients with Stage II - III (IASLC-WCLC 2023)
Recent studies have shown a promising effect of Osimertinib in adjuvant settings... The frequency of EGFR mutation in postoperative lung cancer was comparable to the occurrence in the general lung cancer population. EGFR mutation did not affect DFS and OS in patients after resection.
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR expression • EGFR positive • EGFR negative
|
Tagrisso (osimertinib)
8ms
A CT-based Deep Learning Radiomics Nomogram for the Prediction of EGFR Mutation Status in Head and Neck Squamous Cell Carcinoma. (PubMed, Acad Radiol)
A DLRN using CECT was built to predict EGFR mutation in HNSCC. The model showed high predictive ability and may aid in treatment selection and patient prognosis.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR positive • EGFR negative
9ms
The long-term outcome of epidermal growth factor receptor mutation in stage IV lung adenocarcinoma patients. (ERS 2023)
The positive EGFR mutation results imply the better prognosis due to the evolution of targeted therapy. The finding of T790M mutation after the initial targeted therapy is common and the prognosis is better after the use of Osimertinib.; Public health; Endoscopy and interventional pulmonology; Cell and molecular biology; General respiratory patient care; Respiratory intensive care; Epidemiology; Surgery
Clinical • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR positive • EGFR negative
|
Tagrisso (osimertinib)
10ms
Pediatric type diffuse high grade glioma, H3-wildtype and IDH wildtype: Two adult cases with interesting histopathologic and molecular findings (AANP 2023)
Also, we are showing their expanded neuro-oncology panel and the methylation profiling. More case studies are needed for further characterization of this tumor.
Clinical
|
EGFR (Epidermal growth factor receptor) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • ATRX (ATRX Chromatin Remodeler) • GFAP (Glial Fibrillary Acidic Protein)
|
EGFR amplification • EGFR negative • IDH wild-type
11ms
Analytical Performance of a Highly Sensitive System to Detect Gene Variants Using Next-Generation Sequencing for Lung Cancer Companion Diagnostics. (PubMed, Diagnostics (Basel))
The identity rates were as follows: EGFR positive, 100% (95% confidence interval, 95.5-100); EGFR negative, 90.9 (82.2-96.3); BRAF positive, 100 (59.0-100); BRAF negative, 100 (94.9-100); KRAS G12C positive, 100 (92.7-100); KRAS G12C negative, 100 (93.0-100); ALK positive, 96.7 (83.8-99.9); ALK negative, 98.4 (97.2-99.2); ROS1 positive, 100 (66.4-100); ROS1 negative, 99.0 (94.6-100); MET positive, 98.0 (89.0-99.9); MET negative 100 (92.8-100); RET positive, 93.8 (69.8-100); RET negative, 100 (94.9-100). The analytical performance showed that the panel could handle various types of biopsy samples obtained by routine clinical practice without requiring strict pathological monitoring, as in the case of conventional NGS panels.
Journal • Next-generation sequencing • Companion diagnostic
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
BRAF V600E • KRAS G12C • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • ALK positive • EGFR T790M • ROS1 positive • KRAS G12 • EGFR positive • MET positive • EGFR negative • ALK negative • KRAS deletion • RET positive